Selexis SA CSO to Speak at the Human Antibodies and Hybridomas 2011 Conference

Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal Antibodies and Fc:Fusion Proteins

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pierre-Allain Girod, Ph.D., Selexis Chief Scientific Officer

Pierre-Allain Girod, Ph.D., Selexis Chief Scientific Officer

The CHO cell for the production of Fc:fusion at high level is notorious for poor performance. Selexis has identified components of the secretion network able to enhance the yield of recombinant proteins.

Geneva, Switzerland (PRWEB) August 31, 2011

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today the Company’s chief scientific officer, Pierre-Allain Girod, Ph.D., will present, “Engineering CHO Cell Line For Enhanced Production of MAbs and Fc:Fusion Proteins” on Tuesday, November 8, 2011 at the 16th Annual Human Antibodies and Hybridomas Conference being held November 7 – 9, 2011 in Cannes, Frances at the Novotel Cannes Montfleury.

Presentation Abstract:

The Chinese hamster ovary (CHO) cell line is the predominant host for the production of therapeutic proteins. However, the CHO cell for the production of Fc:fusion at high level is notorious for poor performance. We identified components of the secretion network able to enhance the yield of recombinant proteins. Co-expression of secretion components improved cell lines expression at protein concentrations of greater than 1 gr/L in a fed-batch process.

For more information and registration, please visit the Human Antibodies and Hybridomas 2011 Conference website at http://www.meetingsmanagement.com/hah_2011.
About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information, visit http://www.selexis.com

###


Contact

Attachments

Pierre-Allain Girod, Ph.D., Selexis Chief Scientific Officer Pierre-Allain Girod, Ph.D., Selexis Chief Scientific Officer

Pierre-Allain Girod, Ph.D., Selexis Chief Scientific Officer


Selexis Corporate Logo


CHO Cells, Fc:Fusion Proteins, MAbs, Antibodies Colony of Selexis SURE CHO-M cells

Colony of Selexis SURE CHO-M Cells